Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia

Kasper, S.; Hale, Anthony S.; Azorin, Jean‐Michel; Möller, Hans‐Jürgen

doi:10.1007/pl00014165

Cited by 28 publications

(16 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, quetiapine, due to its low level of striatal D 2 occupancy, has a low propensity to induce EPS (Hellewell et al, 1998;Kasper et al, 1999). Indeed, previous studies have shown quetiapine to be associated with a placebo-level incidence of EPS across the dose range (Arvanitis et al, Borison et al, 1996Small et al, 1997).…”

Section: Introductionmentioning

confidence: 93%

An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms

Timdahl

Carlsson

Stening

2007

Human Psychopharmacology

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 93%

An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms

Timdahl

Carlsson

Stening

2007

Human Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…19,20 Nevertheless, certain critical clinical issues remain uncertain. Improved tolerability with the newer drugs has been widely reported in terms of sideeffects and subjective experience.…”

Section: Therapeutic Efficacymentioning

confidence: 99%

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment

Lewis

Davies²,

Jones³

et al. 2006

Health Technol Assess

134

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. Declared competing interests of authors: SW Lewis received support for travel to meetings and honoraria for consultancies from AstraZeneca, Lilly, BristolMyersSquibb, Pfizer, Janssen, Wyeth, Lundbeck, GlaxoSmithKline and Novartis. L Davies received funding for preparing papers and attendance at meetings from Janssen, Hoechst Marion Roussel, Pfizer, AstraZeneca and Lundbeck, and project funding from Novartis. PB Jones received travel support to academic meetings from companies manufacturing drugs used in this study, and unrestricted use of honoraria and consultancy fees for some work for academic use in his department and elsewhere. TRE Barnes received travel support to academic meetings and honoraria for consultancy from companies manufacturing drugs used in this study, plus the award of a grant from Sanofi-Synthelabo for an investigator-initiated study. RM Murray received honoraria and advisory fees from pharmaceutical companies (paid into departmental research funds). R Kerwin received honoraria and advisory fees from pharmaceutical companies and received research grants for non-clinical research from Novartis. D Taylor received honoraria for a lecture and consultancy from manufacturers of atypical antipsy...

show abstract

“…The efficacy against a broader spectrum of symptoms as well as their lower likelihood of extrapyramidal symptoms have led to an increased use of this class of medication (Kasper et al, 1999(Kasper et al, , 2001.…”

Section: Introductionmentioning

confidence: 99%

Effects of Olanzapine and Ziprasidone on Glucose Tolerance in Healthy Volunteers

Sacher

Mossaheb

Spindelegger

et al. 2007

Neuropsychopharmacol

Self Cite

View full text Add to dashboard Cite

Atypical antipsychotics have been linked to a higher risk for glucose intolerance, and consequentially the development of type 2 diabetes mellitus (DM2). We have therefore set out to investigate the acute effects of oral administration of olanzapine and ziprasidone on whole body insulin sensitivity in healthy subjects. Using the standardized hyperinsulinemic euglycemic clamp technique we compared whole body insulin sensitivity of 29 healthy male volunteers after oral intake of either olanzapine 10 mg/day (n ¼ 14) or ziprasidone 80 mg/day (n ¼ 15) for 10 days. A significant decrease (po0.001) in whole body insulin sensitivity from 5.7 ml/h/kg ( ¼ mean, SM ¼ 0.4 ml/h/kg) at baseline to 4.7 ml/h/kg ( ¼ mean, SM ¼ 0.3 ml/h/kg) after oral intake of olanzapine (10 mg/day) for 10 days was observed. The ziprasidone (80 mg/day) group did not show any significant difference (5.2 ± 0.3 ml/h/kg baseline vs 5.1 ± 0.3 ml/h/kg) after 10 days of oral intake. Our main finding demonstrates that oral administration of olanzapine but not ziprasidone leads to a decrease in whole body insulin sensitivity in response to a hyperinsulinemic euglycemic challenge. Our finding is suggestive that not all atypical antipsychotics cause acute direct effects on glucose disposal and that accurate determination of side effect profile should be performed when choosing an atypical antipsychotic.

show abstract

Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia

Cited by 28 publications

References 48 publications

An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms

An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment

Effects of Olanzapine and Ziprasidone on Glucose Tolerance in Healthy Volunteers

Contact Info

Product

Resources

About